Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033006 | 0.84 | ALDH1A1 (0.63) | ALDH1A1HDAC8HDAC1HDAC6MAPK1 | |
| SCHEMBL10033005 | 0.80 | TDP1 (0.63) | RORCALDH1A1HDAC8HDAC1HDAC6 | |
| SCHEMBL23501539 | 0.78 | HDAC8 (0.47) | RORCALDH1A1HDAC8HDAC1HDAC6 | |
| SCHEMBL848439 | 0.78 | RORC (0.64) | RORCALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL12144981 | 0.78 | ALOX5 (0.49) | RORCALDH1A1HDAC8HDAC1HDAC6 | |
| SCHEMBL1133884 | 0.77 | RORC (0.67) | RORCALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL28493212 | 0.77 | RORC (0.62) | RORCALDH1A1MAPK1POLBTDP1 | |
| SCHEMBL8413542 | 0.76 | RORC (0.66) | RORCALDH1A1POLBTDP1SMN1; SMN2 | |
| SCHEMBL17603152 | 0.75 | RORC (0.78) | RORCALDH1A1HDAC6SMN1; SMN2 | |
| SCHEMBL721054 | 0.75 | MAPK1 (0.57) | ALDH1A1HDAC8KCNK3KCNK9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2022-11-10 | — | — | US | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| US-10959970-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2021-03-30 | — | — | US | disclosed |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| EP-3744398-A1 | ALKYLAMIDO COMPOUNDS AND USES THEREOF | Nogra Pharma Limited (IE) | 2020-12-02 | — | — | EP | disclosed |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2020-06-18 | — | — | US | disclosed |
| EP-2811993-B1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LTD (IE) | 2019-10-09 | — | — | EP | disclosed |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2015-02-19 | — | — | US | disclosed |
| US-8796334-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8796334-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8754127-B2 | Alkylamido compounds and uses thereof | NOGRA PHARMA LIMITED (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8754127-B2 | Alkylamido compounds and uses thereof | NOGRA PHARMA LIMITED (IE) | 2014-06-17 | — | — | US | disclosed |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | RORC 1314/4885ALDH1A1 2715/4885HDAC8 697/4885 |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | RORC 1314/4885ALDH1A1 2715/4885HDAC8 697/4885 |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | RORC 1314/4885ALDH1A1 2715/4885HDAC8 697/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | RORC 1256/4885ALDH1A1 664/4885HDAC8 815/4885 |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | RORC 61/4885ALDH1A1 159/4885HDAC8 161/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | RORC 490/4885ALDH1A1 53/4885HDAC8 472/4885 |
| US-10959970-B2 | Methods of treating hair related conditions | PPARA, PPARG, PPARD | RORC 61/4885ALDH1A1 159/4885HDAC8 161/4885 |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | RORC 61/4885ALDH1A1 159/4885HDAC8 161/4885 |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | RORC 1314/4885ALDH1A1 2715/4885HDAC8 697/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | RORC 1256/4885ALDH1A1 664/4885HDAC8 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.